title: Linear mixed-effects model of QTc prolongation for olmesartan medoxomil.
authors.affiliation: Daiichi Sankyo Pharma Development, Edison, NJ, USA.
authors.forename: SaeHeum
authors.initials: S
authors.lastname: Song
authors.affiliation: Daiichi Sankyo Co, Ltd, Tokyo, Japan.
authors.forename: Nobuko
authors.initials: N
authors.lastname: Matsushima
authors.affiliation: Daiichi Sankyo Pharma Development, Edison, NJ, USA.
authors.forename: James
authors.initials: J
authors.lastname: Lee
authors.affiliation: Daiichi Sankyo Pharma Development, Edison, NJ, USA.
authors.forename: Jeanne
authors.initials: J
authors.lastname: Mendell
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D016014:Linear Models; D008133:Long QT Syndrome; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D000068557:Olmesartan Medoxomil / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D000068557:Olmesartan Medoxomil
keywords: QTc interval; angiotensin receptor blocker; cardiac safety; hypertension; olmesartan